Correlation Between Lyra Therapeutics and Adagene
Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and Adagene at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and Adagene into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lyra Therapeutics and Adagene, you can compare the effects of market volatilities on Lyra Therapeutics and Adagene and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of Adagene. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and Adagene.
Diversification Opportunities for Lyra Therapeutics and Adagene
0.25 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Lyra and Adagene is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and Adagene in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adagene and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with Adagene. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adagene has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and Adagene go up and down completely randomly.
Pair Corralation between Lyra Therapeutics and Adagene
Given the investment horizon of 90 days Lyra Therapeutics is expected to generate 0.85 times more return on investment than Adagene. However, Lyra Therapeutics is 1.18 times less risky than Adagene. It trades about 0.02 of its potential returns per unit of risk. Adagene is currently generating about 0.0 per unit of risk. If you would invest 21.00 in Lyra Therapeutics on December 1, 2024 and sell it today you would earn a total of 0.00 from holding Lyra Therapeutics or generate 0.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Lyra Therapeutics vs. Adagene
Performance |
Timeline |
Lyra Therapeutics |
Adagene |
Lyra Therapeutics and Adagene Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Lyra Therapeutics and Adagene
The main advantage of trading using opposite Lyra Therapeutics and Adagene positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, Adagene can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adagene will offset losses from the drop in Adagene's long position.Lyra Therapeutics vs. CytomX Therapeutics | Lyra Therapeutics vs. Assembly Biosciences | Lyra Therapeutics vs. Achilles Therapeutics PLC | Lyra Therapeutics vs. Instil Bio |
Adagene vs. Aerovate Therapeutics | Adagene vs. Acrivon Therapeutics, Common | Adagene vs. Rezolute | Adagene vs. AN2 Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Complementary Tools
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Transaction History View history of all your transactions and understand their impact on performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |